{"schema_version":"secwatch.filing_event.v1","accession":"0001640334-24-001908","form_type":"8-K","ticker":"LEXX","cik":"0001348362","company_name":"Lexaria Bioscience Corp.","filed_at":"2024-12-18T23:59:59+00:00","discovered_at":"2026-05-14T18:03:08.234598+00:00","generated_at":"2026-05-29T01:56:30.485643+00:00","sec_items":["1.0"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Lexaria Bioscience signs ~AUD$5.1M clinical study agreement with Novotech for GLP-1-H24-4 trial","bullets":["Effective Dec 2, 2024: Novotech as CRO for DehydraTECH Cannabidiol + GLP-1 agonists in pre- and Type II Diabetes.","Aggregate costs ~AUD$5.1 million; upfront payments ~AUD$414,600 (direct) and ~AUD$347,800 (pass-through).","Lexaria AU can terminate the Project Agreement with or without cause upon 90 days' notice.","Initial start-up work already completed under a separate Start-Up Agreement."],"urls":{"canonical":"https://secwatch.observer/filing/0001640334-24-001908","json":"https://secwatch.observer/filing/0001640334-24-001908.json","markdown":"https://secwatch.observer/filing/0001640334-24-001908.md","text":"https://secwatch.observer/filing/0001640334-24-001908.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1348362/000164033424001908/0001640334-24-001908-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1348362/000164033424001908/lxrp_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-29T01:56:30.485643+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}